Developmental Research Program
发展研究计划
基本信息
- 批准号:8719049
- 负责人:
- 金额:$ 8.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-07-01 至
- 项目状态:未结题
- 来源:
- 关键词:AreaClinical TrialsCollaborationsCommunitiesCoupledCutaneousDataDermatologyDevelopmentDiagnosisDirect CostsDoctor of MedicineFundingFunding OpportunitiesFutureGiftsGoalsHumanInstitutesLeadershipLettersOutcomePatientsPhasePilot ProjectsPlayPreventionProcessReproduction sporesResearchResearch ActivityResearch ContractsResearch PersonnelResearch Project GrantsResourcesRoleScienceScientific Advances and AccomplishmentsSkin CancerSourceT-Cell LymphomaTranslational ResearchTranslationsUnited States National Institutes of HealthYale Cancer Centeranticancer researchbasecancer riskcareer developmentexpectationinnovationinterestmeetingsmelanomanew technologyoncologyoutcome forecastprogramstechnology development
项目摘要
The primary goal of the Yale SPORE in Skin Cancer Developmental Research Program (DRP) is to provide limited support (maximum of $50,000/year, typically for no more than two years) for a broad spectrum of innovative skin cancer pilot projects (involving research, resources, and technology development applicable to human skin cancer risk, prevention, diagnosis, prognosis, or treatment). Such feasibility/pilot projects must have promising translational research potential, i.e., there must be the expectation that they can evolve, or be incorporated into, full projects with an unequivocal translational component, such that they could replace other completed or sub-optimally progressing projects previously funded within this SPORE. An alternative satisfactory outcome for a funded pilot project would be its development into a research project capable of successfully competing for independent, ROI-type funding. A total of at least $250,000/year will be utilized for Developmental Research Projects ($100,000 in direct costs;, $100,000 in institutional matching funds guaranteed by the Yale Cancer Center, and at least $50,000/year guaranteed by the Department of Dermatology to specifically be used to help support translation to early phase clinical trials of scientific advances made as a result of YSPORE primary/full, developmental or career development projects. A second goal of this DRP is broaden the base of investigators within the Yale research community who are actively engaged in research related to human skin cancer. During Its initial five-year funding period, from 31 new applications for funding, the YSPORE DRP has funded 16 different projects (15 related to melanoma, 1 to cutaneous T cell lymphoma) involving 27 different investigators from 12 different departments/sections. Six additional pilot projects (9 investigators from 8 departments) received more limited support via the YSPORE Administrative Core discretionary funds. A very generous gift from a grateful patient allowed the establishment of the Milstein Meyer Center for Melanoma Research, funds from which were used to further diversify YSPORE pilot/developmental research in melanoma by providing support for five additional projects (8 investigators in five departments).
耶鲁大学孢子皮肤癌开发研究计划(DRP)的主要目标是为一系列创新的皮肤癌试点项目(涉及适用于人类皮肤癌风险、预防、诊断、预后或治疗的研究、资源和技术开发)提供有限的支持(最高50,000美元/年,通常不超过两年)。这种可行性/试点项目必须具有有前景的翻译研究潜力,即必须期望它们能够演变或被纳入具有明确翻译成分的完整项目,以便它们能够取代以前在该孢子内资助的其他已完成或进展不佳的项目。一个由资金资助的试点项目的另一个令人满意的结果是,它将发展成为一个能够成功竞争独立的、ROI类型的资金的研究项目。每年至少有250,000美元将用于开发研究项目(100,000美元为直接成本;100,000美元由耶鲁癌症中心担保的机构匹配资金;以及至少50,000美元/年由皮肤科担保的资金,专门用于支持将YSPORE初级/全面、发展或职业发展项目所取得的科学进步转化为早期临床试验。DRP的第二个目标是扩大耶鲁大学研究界的研究人员基础,他们积极参与与人类皮肤癌相关的研究。在最初的五年资助期内,YSPORE DRP从31个新的资金申请中,资助了16个不同的项目(15个与黑色素瘤有关,1个与皮肤T细胞淋巴瘤有关),涉及来自12个不同部门/部门的27名不同研究人员。另外6个试点项目(来自8个部门的9名调查员)通过YSPORE行政核心可自由支配基金得到了更有限的支持。一位心怀感激的患者的慷慨捐赠使米尔斯坦·迈耶黑色素瘤研究中心得以成立,该中心的资金用于通过支持另外五个项目(五个部门的8名研究人员),进一步丰富YSPORE黑色素瘤试点/开发研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT E. TIGELAAR其他文献
ROBERT E. TIGELAAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT E. TIGELAAR', 18)}}的其他基金
相似海外基金
From lymphatics to evaluating resolution therapeutics in clinical trials
从淋巴管到评估临床试验中的解决疗法
- 批准号:
MR/Y013050/1 - 财政年份:2024
- 资助金额:
$ 8.79万 - 项目类别:
Fellowship
RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network
RareKids-CAN:儿科罕见病临床试验和治疗网络
- 批准号:
495575 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别:
Operating Grants
Unbiased estimation in hierarchical models for Clinical trials
临床试验分层模型中的无偏估计
- 批准号:
2884930 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别:
Studentship
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10895949 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别:
CONTRACEPTIVE CLINICAL TRIALS NETWORK, CCTN - FEMALE SITES 'CORE FUNCTION ACTIVITIES
避孕临床试验网络,CCTN - 女性站点的核心功能活动
- 批准号:
10891325 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别:
ISimcha Technology Platform for Recruiting a Diverse Population of Older Adults into Clinical Trials
ISimcha 技术平台,用于招募不同的老年人群进行临床试验
- 批准号:
10761602 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
- 批准号:
10758129 - 财政年份:2023
- 资助金额:
$ 8.79万 - 项目类别: